An inspirational evening to benefit The Israel Cancer Research Fund (ICRF) was held at the residence of Alice and Harry Adjmi. More than 400 people—both young and old—came to listen to the insights of four cancer specialists including guest of honor Dr. Avram Hershko, an ICRF scientist and recipient of the 2004 Nobel Prize in Chemistry. His research led to the development of Velcade, a drug for the treatment of multiple myeloma, cervical cancer and cystic fibrosis.
Other speakers included Dr. Lawrence Helsen, a renowned medical oncologist who was the director of Phase 3 clinical trials of Zoladex ICI; Dr. Alexander Swistel, a noted surgeon, who pioneered many new advances including sentinel lymph node biopsy and oncoplastic surgery, and Dr. Yashar Hirshaut, chairman of the ICRF and an oncologist in private practice who has dedicated his life to fighting the war on cancer. Dr. Hirshaut is the author of Breast Cancer: The Complete Guide, whose fifth edition will be released by Random House in October. He reminded us to remain focused on the ICRF mission to help Israeli scientists eliminate cancer by ensuring the acceleration of research.
Master of Ceremonies Harry Adjmi hosted the event in memory of his late mother, Lillian Adjmi, who passed away from breast cancer. Mr. Adjmi remarked how pleased he was to have so many young people gathered at his home to learn first hand about the importance of hesed.
Charles Ben-Dayan, ICRF board of trustees member and his wife, Arielle, who hosted the event two years ago, observed how interest in the organization has grown in the community. Many of those who attended came not only to show their support but also to find answers to their questions about cancer.
Sadie Jemal-Meyers served as chairperson and noted how moved she was by the energy of the evening. Over the years, Sadie has become a strong supporter of ICRF and feels that the scientists in Israel are at the forefront of finding the cure for cancer. She reminded the members of the community of what John Paul Jones said before he conquered the British in 1776: “I have not yet begun to fight.” The battle to eradicate cancer has not yet been won.
Since its inception in 1975, ICRF has supported and encouraged innovative research by Israeli scientists and has been the largest single source of private funds for cancer research in Israel. With world-class universities and research institutions, Israel has developed an international reputation as a center for medical and scientific research. Israel is also rich in scientific talent, with more doctors and scientists per capita than any other nation. In addition, Israel offers a unique population of diverse and defined ethnic groups that give scientists an unparalleled opportunity to study the genetic and environmental factors that can lead to cancer.
ICRF has invested close to $35 million in more than 1,600 research grants for scientists at every major university and research institute in Israel. The organization’s financial support has helped to produce two Nobel Prize winners. ICRF grantees have earned distinguished honors including the Wolf Prize, The Lasker Award in Basic Medical Research and The Israel Prize. ICRF-funded research has led to the development of lifesaving drugs such as Gleevec, Doxil and Velcade; the discovery of the location and chemical nature of the p53 tumor-suppressor gene and the identification of the “Philadelphia Chromosome,” the first abnormal chromosome found in leukemia.
ICRF grants are chosen by a 26-member panel composed of leading scientists from the US and Canada, and modeled on the NIH’S review process.
For additional infomation about the organization please contact the Israel Cancer Research Fund, 1290 Avenue of the Americas, Suite 550, New York, New York, (212) 969-9800, www.icrfonline.org, or email: mail@icrfny.com.
